169 results about "Neutrophilic Myelocytes" patented technology

The present invention provides a highly sensitive method of diagnosing inflammatory bowel disease (IBD) in an individual. The method includes the steps of isolating a sample from the individual; determining by non-histological means whether the sample is positive for anti-neutrophil cytoplasmic antibodies (ANCA); determining whether the sample is positive for anti-Saccharomyces cerevisiae immunoglobulin A (ASCA-IgA); determining whether the sample is positive for anti-Saccharomyces cerevisiae immunoglobulin G (ASCA-IgG); and diagnosing the individual as having IBD when the sample is positive for ANCA, ASCA-IgA or ASCA-IgG, and diagnosing the individual as not having IBD when the sample is negative for ANCA, ASCA-IgA and ASCA-IgG, provided that the method does not include histological analysis of neutrophils.

This invention relates to a method of inhibiting the overactivity of phagocytes or lymphocytes in an individual by administering to said individual an effective amount of a lignan, wherein i) the phagocytes are neutrophils and the lignan is hydroxymatairesinol or matairesinol or mixtures thereof, or ii) the phagocytes are cells of myeloid origin and the lignan is enterolactone or hydroxymatairesinol or mixtures thereof, or iii) the lymphocytes are T-lymphocytes and the lignan is hydroxymatairesinol, matairesinol or enterolactone or mixtures thereof. Furthermore, this invention concerns a method of treating or preventing an acute ischemia-reperfusion injury or a chronic condition, caused by overactivity of phagocytes or lymphocytes in an individual, said method comprising decreasing the activity of phagocytes in an individual by administering to said individual an effective amount of a lignan.

A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.

The invention discloses a new Chinese medicine composite for treating appendicitis and a preparation method thereof. The Chinese medicine composite is prepared by the following ingredients of grassleaf sweetflag rhizome, squama manitis, styrax, lysimachia foenum-graecum, lignum dalbergiae odoriferae, radix et rhizoma rhei, ligusticum chuanxiong, Lignum aquilariae resinatum, rhizoma cyperi, honeysuckle flower, Chinese violet, weeping forsythia, dandelion, stir-fried frankincense, stir-fried myrrh, radix sophorae flavescentis, ramulus cinnamomi, radix paeoniae alba, radix paeoniae rubra, folium isatidis, common andrographis herb, rhizoma sparganii and rhizoma curcumae, and the like. The Chinese medicine composite can be prepared to be any common oral preparation according to the conventional Chinese medicine preparation method. The Chinese medicine composite can obviously improve right lower quadrant pain, increased body temperature, emesia, neutrophilic leukocytosis and the like, effectively block appendix gangrene and perforation, and complicate localized or diffuse peritonitis, which has definite clinical effect, obvious curative effect and fast desired effect. Due to the combination of the medicines both as food and medicine according to state-promulgated pharmacopoeia, the Chinese medicine composite of the invention has the advantages of low cost, basically no toxic side effect and the like.

A method of inhibiting complement activation mediated by C3b inhibitors in a subject is provided. The method includes administering a C3b inhibitor to the subject to inhibit at least one of C3b binding to factors B and properdin, to inhibit C3 cleavage, to inhibit the activation of neutrophils, monocytes, platelets, and endothelium; or to inhibit the formation of C3a, C5a, and MAC.

The invention discloses a tumor predictor based on dynamic spectra. The tumor predictor comprises a dynamic spectrum detecting module, a data processing module and a display module, wherein the dynamic spectrum detecting module is used for detecting blood composition data and transmitting the detected blood composition data to the data processing module, the data processing module is used for receiving the blood composition data transmitted by the dynamic spectrum detecting module, processing the data and transmitting processed data to the display module, and the display module is used for receiving the data processed by the data processing module and then displaying the data. A tumor prediction idea based on neutrophil to lymphocyte ratio (NLR) is adopted, tumor prevention can be achieved through non-invasive blood composition detection, tumor prediction and analysis are conducted according to the number of neutrophils (N), the number of lymphocytes (L) and the NLR, equipment is simple, using is convenient, and non-invasive tumor prevention and detection can be achieved.

N-(2-aryl-propionyl)-amides of formula (I) are described. The process for their preparation and pharmaceutical preparations thereof are also described. The amides of the invention are useful in the prevention and treatment of tissue damage due to the exacerbate recruitment of polymorphonuclear neutrophils (leukocytes PMN) at the inflammatory sites. In particular, the invention relates to the R enantiomers of N-(2-aryl-propionyl)amides of formula (I) for use in the inhibition of the chemotaxis of neutrophils induced by IL-8. The compounds of the invention are used in the treatment of psoriasis, ulcerative cholitis, glomerular nephritis, acute respiratory insufficiency, idiopathic fibrosis, and rheumatoid arthritis.

The invention relates to the design of organic fluorescent materials, in particular to a small molecular fluorescent compound with polymerization-induced emission characteristics, which can display emitted light in a second near-infrared window (1000-1700 nm) and can provide imaging for deep tissues at an ultrahigh signal-to-noise ratio. For example, neutrophils carrying the compounds of the invention can penetrate the brain, and inflammation located deep in brain tissue can be observed through the intact scalp and skull.

The invention discloses application of mycoplasma bovis secretory protein MbovP570 in preparation of mycoplasma bovis diagnostic reagents, drugs or vaccines, and belongs to the technical field of animal infectious disease prevention and treatment. The mycoplasma bovis secretory protein MbovP570 has a sequence as shown in SEQ ID NO: 1. 2 is an amino acid sequence shown in the specification; test proves that the mycoplasma bovis secretory protein MbovP570 has antigenicity and can be used for detecting mycoplasma bovis. The protein can react with mycoplasma bovis positive serum instead of mycoplasma bovis negative serum, the protein can induce bovine macrophages to highly express IL-8 and IL-12, IL-8 can activate neutrophils, and IL-12 can activate NK cells and T cells. Therefore, it is believed that MbovP570 can activate a host immune system and has important potential in research and development of new drugs and vaccines.

The invention provides an inducer for in-vitro rapidly inducing neutrophil to generate extracellular traps and an induction method thereof. The inducer is prepared from the following components: a pretreatment component A which is selected from IgG2 and IgG4; an induction component B which is selected from APD or a mixture of APD and PMA; and lipopolysaccharide. Meanwhile, the invention also provides an inducation method for in-vitro rapidly inducing the neutrophil to generate extracellular traps (NETs). The induction method comprises the following steps: separating peripheral blood neutrophil; and using the inducer comprising the component A, component B and lipopolysaccharide to induce the neutrophil to form NETs. The inducer and induction method provided by the invention have good application prospect in the aspects for rapidly detecting mammal NETs and screening for promoting or inhibiting the NETs to generate a drug.

The invention provides application of CD177 in preparation of a product for diagnosing biliary atresia, and relates to the technical field of molecular diagnosis. According to the invention, by detecting a large number of biliary atresia child patient samples and combining animal experiments, it is proved that the number of CD177+ neutrophile granulocytes in biliary atresia peripheral blood and liver tissue can serve as a powerful index for evaluating the liver injury degree at first; and therefore, detection of CD177 genes, CD177 protein or the CD177+ neutrophile granulocytes can serve as a more convenient, direct and accurate method for clinically evaluating the illness state of biliary atresia child patients. The invention also proves that CD177 has a pro-inflammatory effect in biliaryatresia; and the inhibitor of CD177 can be used for research and development of drugs for treating biliary atresia.

The invention relates to a quantitative device for human neutrophil apolipoprotein (HNL) homodimer, which belongs to the technical field of immunological detection. Consists of 5-fold sample dilution, 25-fold washing solution, HNL homodimer standard stock solution, 96-well enzyme-labeled plate coated with anti-HNL antibody, enzyme-labeled anti-HNL antibody, U-bottom 96-well plate, sealing film , enzyme substrate solution and stop solution. The anti-HNL antibody coated on the enzyme plate of the present invention and the enzyme-labeled anti-HNL antibody are the same antibody, thereby simply realizing the quantification of the HNL homodimer concentration. In addition, only two steps of incubation and one step of washing are required during the use of the device, thereby significantly shortening the detection time. Therefore, the invention has the advantages of simple preparation, convenient use, short test time and the like. The invention can be used for the detection and monitoring of diseases (such as acute bacterial infection) marked by HNL homodimer, and thus has great laboratory research and clinical application value.

The invention discloses an immunochromatography device for synchronously and quantitatively detecting different molecular forms of human neutrophil lipocalin (HNL) and a preparation method thereof, and belongs to the field of laboratory medicine. The device is composed of sample diluent freeze-dried powder, standard substance freeze-dried powder and an immunochromatography test strip. The immunochromatography test strip is composed of a liner plate, two blood filtration membranes, a sample flow pad, a UCP combination pad, an analysis membrane and an absorption pad. The UCP combination pad is coated with an antibody capable of resisting three molecular forms of HNL with UCP markers; the analysis membrane is provided with three parallel detection regions (T1, T2 and T3) and a quality control region C, and the three detection regions are coated with an antibody capable of resisting a matrix metal protease-9, an antibody capable of resisting a monomer HNL and an antibody capable of resisting homodimer; the quality control region C is coated with an antibody from animal immune globulin with the UCP marker. One sample can detect three molecular forms of HNL in a combined mode on the same test strip, and the device has the advantages of being rapid, quantitative, easy and convenient to use and the like and has the large scientific research and clinic application prospects.

Embodiments are directed to: (i) neutrophil secreted factors that have the capacity to kill a broad range of cancer cells without affecting the viability of non-cancer cells. Two neutrophil killing factors have been identified by the inventors: (1) eosinophil cationic protein (ECP) and (2) neutrophil elastase (ELANE); or (ii) therapeutic compositions that include CD95 degrading polypeptide components and methods of treating cancer with the same.